Pacira BioSciences (PCRX) Change in Cash (2010 - 2026)

Pacira BioSciences' Change in Cash history runs 17 years deep, the most recent figure standing at -$14.2 million for Q1 2026.

• On a quarterly basis, Change in Cash fell 308.29% year-over-year to -$14.2 million in Q1 2026; TTM through Mar 2026 was -$139.3 million, a 239.92% decrease from a year earlier, with the FY2025 full-year figure at -$118.2 million, down 195.75% from the prior year.
• Change in Cash slipped to -$14.2 million in Q1 2026 per PCRX's latest filing, from $11.0 million in the prior quarter.
• Across five years, Change in Cash topped out at $63.0 million in Q2 2024 and bottomed at -$358.8 million in Q1 2022.
• The 5-year median for Change in Cash is $6.8 million (2025), against an average of -$26.0 million.
• Across the five-year window, Change in Cash soared 1125.15% in 2023 and slumped 13952.85% in 2025, its largest moves.
• Year by year, Change in Cash stood at -$5.3 million in 2022, then surged by 1125.15% to $54.2 million in 2023, then slumped by 43.13% to $30.8 million in 2024, then tumbled by 64.44% to $11.0 million in 2025, then slumped by 229.97% to -$14.2 million in 2026.
• Per Business Quant, the three latest PCRX Change in Cash figures stand at -$14.2 million (Q1 2026), $11.0 million (Q4 2025), and -$152.9 million (Q3 2025).